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I
ron is the most abundant transitional
metal in the body. It has long been
recognized that iron overload can in-
crease the risk of diabetes, particularly in
iron-overload states such as hemochro-
matosis and recurrent transfusions in
diseases like thalassemia. Furthermore, a
large body of epidemiological evidence
suggests that an increase in dietary iron
(as heme, mainly from meat and meat
products) is associated with an increased
risk of diabetes (1). In contrast, iron de-
ﬁciency (over time one of the most com-
monnutritionaldeﬁcienciesinthe world)
may lower the risk of diabetes. Indeed, it
has been suggested that recurrent phle-
botomy may protect against diabetes (2),
although there are no large multicenter,
randomized controlled trials to support
this hypothesis. In addition, iron has
been implicated in the pathogenesis of
renal disease including diabetic ne-
phropathy (1).
Two articles in this issue of Diabetes
Care add to this evidence and report that
prepregnancy dietary heme iron intake is
associated with an increased risk of dia-
betes. The association remains signiﬁcant
even after adjustment for a variety of fac-
tors known to be associated with gesta-
tional diabetes mellitus (GDM). Bowers
et al. (3) studied participants in the
Nurses’ Health Study which has a robust
dataset and fairly reliable information on
dietary intake. Qiu et al. (4) have prospec-
tively studied a similar cohort of over
3,000pregnantwomenandusedfoodfre-
quency questionnaires to assess maternal
diet. Not only was heme iron intake posi-
tively associated with GDM risk, nonheme
iron may have been inversely related to
such risk, although itisnot statisticallysig-
niﬁcant. Women who reported the highest
heme iron intake experienced greater
than a threefold increased risk of GDM.
How might increased iron intake lead
to diabetes? Multiple mechanisms that
link iron with abnormal glucose metabo-
lismhavebeenproposed,includingb-cell
dysfunction and insulin resistance, possi-
blymediated through oxidative stress(1).
Animal studies suggest that iron impairs
b-cell function by inducing oxidative
stress as well as impairing mitochondrial
function and may also decrease glucose
uptake in muscle and adipose sites. Thus
iron plays a role in several important steps
in insulin action and glucose metabolism.
There are very few pathophysiological
studies that explore this association.
It is important to recognize that tradi-
tional methods of measuring iron may not
be the best way to study the pathophysi-
ologicalroleofiron.Forexample,ferritin
is often considered a marker of body iron
stores but is an acute-phase protein that
may be inﬂuenced by coincidental infec-
tionsand,moreimportantly,inthissetting,
bythepresence oflow-gradeinﬂammation
associated with obesity. Moreover, ferritin
itself does not participate directly in the
oxidant reactions related to iron. Critical
to iron’s importance in biological pro-
cesses is its ability to cycle reversibly be-
tween its ferrous and ferric oxidation
states. This precise property, which is es-
sential for its functions, also makes it
very dangerous, because free iron can cat-
alyze the formation of free radicals that
can damage the cell. Thus, from a patho-
physiological standpoint, it is important
to measure iron pools that consist of
chemical forms that can participate in re-
dox cycling, often referred to as catalytic
or labile iron (5–8). Baliga et al. (9) have
previously demonstrated that there is a
poor correlation between catalytic iron
and total body iron stores. Thus mea-
surement of catalytic iron may be impor-
tant in the study of the association of iron
anddiabetesanditscomplications.Recent
data suggest an increase in plasma and
urinary catalytic iron in subjectswith obe-
sity without diabetes, as well as patients
with diabetes-related complications and
acute coronary syndromes (10–12).
The pathological effects of iron accu-
mulation in tissue in iron-overload states
are well known. What is new in the ﬁeld
is the recognition that iron plays an im-
portant role in the pathophysiology of
disease in the absence of systemic iron
overload (1).The concept of ironcontrib-
uting to diabetes is supported by a few
importantrecent animalstudies.Cooksey
et al. (13) have demonstrated that, in
obese mice with type 2 diabetes treated
with an iron-restricted diet as well as an
iron chelator, there were improvements in
glucose metabolism without causing overt
iron deﬁciency. Thus, even at “normal”
levels, iron exerts a detrimental effect on
b-cell function that may be reversible with
removalofiron,eitherthroughphlebotomy
or possibly iron chelation (2). This concept
lends itself to exploring phlebotomy or
iron chelation as potential treatments for
diabetes. Clearly research is needed to
explore this approach in states of lesser
overload with iron or indeed as a poten-
tialtreatmentofdiabetesandprediabetes,
particularlyinthoseidentiﬁed(byappro-
priate testing) as having either excess
nutritional intake or overreactive iron
associated with obesity. Studies in iron-
overload states demonstrate an improve-
ment in glucose metabolism with either
of these modalities (2,14).
Inthecontextofthetwopapersinthis
issue, it is possible that menstruation is
protective for diabetes in premenopausal
women and cessation of menses leads to
some iron accumulation. Clinical trials are
needed to determine whether phlebotomy
orchelationofcatalyticironinwomenwith
GDMandadequateironstorescanimprove
the marked abnormalities seen in insulin
secretion and action associated with this
condition.
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